CoChat

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatment-switching adjustment analysis in all treated patients who received chemotherapy and subsequent immunotherapy. METHODS: alterations, and ECOG performance status ≤1 were randomized 1:1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with chemotherapy (two cycles) or chemotherapy (four cycles, with optional maintenance pemetrexed for the nonsquamous population). Assessments included OS, progression-free survival, and objective response rate. Exploratory analyses included efficacy by tumor PD-L1 expression and histology and in patients who discontinued nivolumab plus ipilimumab with chemotherapy due to treatment-related adverse events (TRAEs), and a treatment-switching adjustment analysis using inverse probability of censoring weighting. RESULTS: With a 47.9-month minimum follow-up for OS, nivolumab plus ipilimumab with chemotherapy continued to prolong OS over chemotherapy in all randomized patients (HR 0.74, 95% CI 0.63 to 0.87; 4-year OS rate: 21% versus 16%), regardless of tumor PD-L1 expression (HR (95% CI): PD-L1<1%, 0.66 (0.50 to 0.86) and ≥1%, 0.74 (0.60 to 0.92)) or histology (squamous, 0.64 (0.48 to 0.84) and non-squamous, 0.80 (0.66 to 0.97)). In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy due to TRAEs (n=61), the 4-year OS rate was 41%. With treatment-switching adjustment for the 36% of patients receiving subsequent immunotherapy in the chemotherapy arm, the estimated HR of nivolumab plus ipilimumab with chemotherapy versus chemotherapy was 0.66 (95% CI 0.55 to 0.80). No new safety signals were observed. CONCLUSIONS: In this 4-year update, patients treated with nivolumab plus ipilimumab with chemotherapy continued to have long-term, durable efficacy benefit over chemotherapy regardless of tumor PD-L1 expression and/or histology. A greater estimated relative OS benefit was observed after adjustment for subsequent immunotherapy use in the chemotherapy arm. These results further support nivolumab plus ipilimumab with chemotherapy as a first-line treatment for patients with metastatic/recurrent NSCLC, including those with tumor PD-L1<1% or squamous histology, populations with high unmet needs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2023-008189

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 OS in (A) all randomized patients, (B) patients with tumor PD-L1 expression <1%, (C) patients with tumor PD-L1 expression ≥1%, (D) patients with squamous histology, and (E) patients with non-squamous histology. Minimum follow-up for OS was 47.9 months. 95% CIs for 4-year OS rates with nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (Chemo) and chemotherapy alone, respectively, were: (A) 17–25 and 12–20; (B) 16–30 and 8–20; (C) 16–27 and 11–22; (D) 13–28 and 5–16; and (E) 17–27 and 14–24. OS, overall survival; PD-L1, programmed death ligand 1.
Figure 1 OS in (A) all randomized patients, (B) patients with tumor PD-L1 expression <1%, (C) patients with tumor PD-L1 expression ≥1%, (D) patients with squamous histology, and (E) patients with non-squamous histology. Minimum follow-up for OS was 47.9 months. 95% CIs for 4-year OS rates with nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (Chemo) and chemotherapy alone, respectively, were: (A) 17–25 and 12–20; (B) 16–30 and 8–20; (C) 16–27 and 11–22; (D) 13–28 and 5–16; and (E) 17–27 and 14–24. OS, overall survival; PD-L1, programmed death ligand 1.CC BY-NC · PubMed Central
Figure 2 OS in patients with (A) tumor PD-L1 expression <1% and squamous histology, (B) tumor PD-L1 expression <1% and non-squamous histology, (C) tumor PD-L1 expression ≥1% and squamous histology, and (D) tumor PD-L1 expression ≥1% and non-squamous histology. Subgroups defined on the basis of baseline tumor PD-L1 expression level in the clinical database and histology per interactive response technology. The 95% CIs for 4-year rates for nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (chemo) and chemo alone, respectively, were: (A) 12–40 and 1–16; (B) 15–31 and 10–25; (C) 11–28 and 6–21; (D) 15–30 and 12–26. OS, overall survival; PD-L1, programmed death ligand 1.
Figure 2 OS in patients with (A) tumor PD-L1 expression <1% and squamous histology, (B) tumor PD-L1 expression <1% and non-squamous histology, (C) tumor PD-L1 expression ≥1% and squamous histology, and (D) tumor PD-L1 expression ≥1% and non-squamous histology. Subgroups defined on the basis of baseline tumor PD-L1 expression level in the clinical database and histology per interactive response technology. The 95% CIs for 4-year rates for nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (chemo) and chemo alone, respectively, were: (A) 12–40 and 1–16; (B) 15–31 and 10–25; (C) 11–28 and 6–21; (D) 15–30 and 12–26. OS, overall survival; PD-L1, programmed death ligand 1.CC BY-NC · PubMed Central
Figure 3 (A) PFS and (B) DOR in the all-randomized population. PFS and DOR were per blinded independent central review. Minimum follow-up for PFS was 47.1 months. The 95% CIs for 4-year rates for nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (Chemo) and chemotherapy alone, respectively, were: (A) 8–15 and 3–8; (B) 17–33 and 6–20. DOR, duration of response; ORR, objective response rate; OS, overall survival. PFS, progression-free survival.
Figure 3 (A) PFS and (B) DOR in the all-randomized population. PFS and DOR were per blinded independent central review. Minimum follow-up for PFS was 47.1 months. The 95% CIs for 4-year rates for nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (Chemo) and chemotherapy alone, respectively, were: (A) 8–15 and 3–8; (B) 17–33 and 6–20. DOR, duration of response; ORR, objective response rate; OS, overall survival. PFS, progression-free survival.CC BY-NC · PubMed Central
Figure 4 DOR for patients with (A) tumor PD-L1 expression <1%, (B) tumor PD-L1 expression ≥1%, (C) squamous histology, and (D) non-squamous histology. The 95% CIs for 4-year rates for nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (chemo) and chemotherapy alone are: (A) 15–45 and not applicable (NA); (B) 15–34 and 7–26; (C) 8–29 and 1–17; and (D) 19–41 and 7–28. DOR, duration of response; ORR, objective response rate; PD-L1, programmed death ligand 1.
Figure 4 DOR for patients with (A) tumor PD-L1 expression <1%, (B) tumor PD-L1 expression ≥1%, (C) squamous histology, and (D) non-squamous histology. The 95% CIs for 4-year rates for nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (chemo) and chemotherapy alone are: (A) 15–45 and not applicable (NA); (B) 15–34 and 7–26; (C) 8–29 and 1–17; and (D) 19–41 and 7–28. DOR, duration of response; ORR, objective response rate; PD-L1, programmed death ligand 1.CC BY-NC · PubMed Central
Figure 5 OS in patients who discontinued nivolumab plus ipilimumab with chemotherapy due to TRAEs. Minimum follow-up for OS was 47.9 months. An exploratory analysis was conducted in patients with TRAEs (reported between first dose and 30 days after the last dose of study treatment) leading to the discontinuation of all components of study treatment. The 95% CIs for the 4-year OS rates for patients who discontinued due to TRAEs and for the all-randomized population, respectively, were 29–53 and 17–25. IPI, ipilimumab; NIVO, nivolumab; NR, not reached; OS, overall survival; TRAEs, treatment-related adverse events.
Figure 5 OS in patients who discontinued nivolumab plus ipilimumab with chemotherapy due to TRAEs. Minimum follow-up for OS was 47.9 months. An exploratory analysis was conducted in patients with TRAEs (reported between first dose and 30 days after the last dose of study treatment) leading to the discontinuation of all components of study treatment. The 95% CIs for the 4-year OS rates for patients who discontinued due to TRAEs and for the all-randomized population, respectively, were 29–53 and 17–25. IPI, ipilimumab; NIVO, nivolumab; NR, not reached; OS, overall survival; TRAEs, treatment-related adverse events.CC BY-NC · PubMed Central
Figure 6 OS in patients in the all-treated population after adjustments using (A) IPCW (primary analysis) and (B) TSE, RPSFT, and IPE (sensitivity analyses) methodologies. Chemo, chemotherapy; IPCW, inverse probability of censoring weighting; IPE, iterative parameter estimation; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival; RPSFT, rank-preserving structural failure time; TSE, two-stage estimation; w/o, without.
Figure 6 OS in patients in the all-treated population after adjustments using (A) IPCW (primary analysis) and (B) TSE, RPSFT, and IPE (sensitivity analyses) methodologies. Chemo, chemotherapy; IPCW, inverse probability of censoring weighting; IPE, iterative parameter estimation; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival; RPSFT, rank-preserving structural failure time; TSE, two-stage estimation; w/o, without.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. O’Byrne K , Popoff E , Badin F , et al . Efficacy of nivolumab + ipilimumab versus other first-line treatments for metastatic NSCLC with PD-L1 <1%: a network meta-analysis. presentation at the IASLC world conference on lung cancer; September 9–12, 2023; Singapore. Available: https://cattendee.abstractsonline.com/meeting/10925/Session/183 [Accessed 22 Sep 2023].
  2. Ramalingam S , Ciuleanu TE , Caro RB , et al . Oral presentation at the IASLC world conference on lung cancer; September 9–12, 2023; Singapore. Abstract OA14.03.

Cited by

See all 65

Metadata

Authors
Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., Mizutani, H., Felip, E., Zurawski, B., Alexandru, A., Paz-Ares, L., Lu, S., John, T., Zhang, X., Mahmood, J., Hu, N., De, T., Santi, I., Penrod, J. R., Yuan, Y., Lee, A., & Reck, M.
Affiliations
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
  • Iuliu Hațieganu University of Medicine and Pharmacy (RO)
  • Department of Medical Oncology, SF Nectarie Oncology Center, Craiova, Romania
  • Hospital Clínico Universitario Virgen de la Victoria (ES)
  • Institut du Thorax (FR)
  • Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
  • Grupo Hospitalar Conceição (BR)
  • German Center for Lung Research (DE)
  • Instituto Oncológico de Córdoba (AR)
  • Jilin Province Tumor Hospital (CN)
  • Saitama Cancer Center (JP)
  • Vall d'Hebron Hospital Universitari (ES)
  • Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland
  • Institutul Oncologic Bucuresti (RO)
  • Universidad Complutense de Madrid (ES)
  • Shanghai Jiao Tong University (CN)
  • Austin Hospital (AU)
  • Bristol-Myers Squibb (United States) (US)
  • PAREXEL International (United States) (US)
Corresponding author
Carbone, David P.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2024-02
Volume
12
Issue
2
Pages
e008189
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4391743853
Cited by
65
References
38
Citations by year
2026: 13 · 2025: 26 · 2024: 26
FWCI
11.06
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
Funders
Bristol Myers Squibb (N/A)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
metastatic non-small cell lung cancer, nivolumab, ipilimumab, immune checkpoint inhibitors, combination immunotherapy, chemotherapy, PD-L1 expression, treatment switching, overall survival, progression-free survival, objective response rate, treatment-related adverse events, inverse probability of censoring weighting, long-term follow-up, lung squamous cell carcinoma, non-squamous cell lung cancer, treatment discontinuation
MeSH terms
Ipilimumab, Nivolumab, Treatment Switching, Adult, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. https://app.cochat.ai/papers/10.1136/jitc-2023-008189
The paper
Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., Mizutani, H., Felip, E., Zurawski, B., Alexandru, A., Paz-Ares, L., Lu, S., John, T., Zhang, X., Mahmood, J., . . . Reck, M. (2024). Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.